By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


GenomeDx Biosciences 

400 – 311 Water Street

Vancouver  British Columbia  BC V6B 1B8  Canada
Phone: 1-888-975-4540 Fax: n/a



Company News
GenomeDx Biosciences Launches Hereditary Cancer Risk Genetic Testing By Color For Prostate Cancer Patients And Families 7/28/2017 9:10:15 AM
GenomeDx Biosciences Announces New York State CLEP Approval Of Decipher Prostate Cancer Tests 6/29/2017 8:57:52 AM
GenomeDx Biosciences Release: Multiple Studies Further Validate The Importance Of Decipher Post-Op In The Treatment Of Prostate Cancer 6/7/2017 7:24:19 AM
GenomeDx Biosciences And Color Collaborate To Further Advance Precision Medicine For Prostate Cancer Patients And Their Families 5/12/2017 8:07:04 AM
GenomeDx Biosciences's Decipher GRID Aids In Development And Validation Of Molecular Subtypes In Prostate Cancer That Predict Response To Hormone Therapy 5/11/2017 11:11:42 AM
GenomeDx Biosciences Launches Decipher Bladder Cancer Classifier Following Publication Of Study On Development, Validation Of Molecular Subtyping In Muscle-Invasive Bladder Cancer Patients 5/10/2017 6:48:50 AM
GenomeDx Biosciences Appoints Michael Rodriguez As Chief Financial Officer 5/9/2017 8:23:19 AM
GenomeDx Biosciences's Decipher Post-Op Demonstrates Positive Impact On Physician, Patient Treatment Decisions In Multicenter Prospective Study 4/25/2017 9:31:19 AM
GenomeDx Biosciences Announces Initiation By Michigan Urological Surgery Improvement Collaborative 3/2/2017 8:02:29 AM
GenomeDx Biosciences Announces Research Collaboration With Astellas (ALPMY) To Identify Genomic Drivers Of Patient Response To XTANDI (Enzalutamide) Capsules 2/1/2017 8:38:16 AM